PSA complexed with alpha-1-anti-chymotrypsin (cPSA TM ) is the moiety in greatest proportion in the serum of men with prostate cancer (CAP). The performance of this analyte has been established primarily in retrospective archival serum. Studies indicate cPSA TM provides the speci®city enhancement of the free-to-total PSA ratio, yet obviates the need to measure two markers. In the present investigation we sought to establish the stability of cPSA TM with longterm storage.
Introduction
Prostate-speci®c antigen (PSA) has revolutionized the management of men with prostatic carcinoma. Its greatest utility has been in early detection or screening. In regions where widespread PSA testing has occurred, there has been a signi®cant stage migration to more favorable presentation at diagnosis. PSA may in part contribute to the reduction in prostate cancer mortality recently observed in the United States.
Despite its widespread utilization, PSA is not the perfect analyte for early detection or screening. This stems both from lack of sensitivity (some men with prostate cancer have`normal' PSA levels) but more importantly lack of speci®city (ie men who have an abnormal PSA but who are shown on biopsy to have benign ®ndings).
Considerable efforts have been made to make PSA more speci®c. Included are the so-called PSA derivatives including PSA velocity, 1 ± 5 age-speci®c PSA, 6 ± 8 and PSA density. 9 ± 11 The biggest advance has been the recognition that PSA circulates in a variety of molecular forms. 12, 13 The ratio of the free PSA to total PSA (free/total PSA) has been shown to enhance speci®city signi®cantly. 14 ± 17 Problems exist with this ratio, including so-called quotient bias resulting in potentially signi®cant discrepancy in clinical testing compared to what is found in the literature. 18, 19 The free/total PSA ratio requires the measurement of two analytes, potentially doubling the cost of PSA testing.
A number of authors have demonstrated lack of stability of the free form of PSA with storage. 16,20 ± 27 While this has been shown to be a greater problem with simple refrigeration, even storage at À70 C or colder has been associated with reduction in the analyte recovery. 16, 20, 21 It has been recognized for a number of years that PSA complexed to the protease inhibitor alpha-1 antichymotrypsin is the moiety that occurs in greater proportion in men with malignancy. A problem in measuring this analyte has been the lack of speci®c assays. Recently the Bayer Corporation developed an assay speci®c for complexed PSA (cPSM TM ). 28 A number of investigators have evaluated this assay. All have demonstrated enhanced performance with improvement in speci®city relative to total PSA. 29 ± 34 We and others showed performance rivaling the free/total PSA ratio 29 ± 31,33 We were interested in evaluating the long-term stability of cPSA TM . This is an important consideration given the fact that virtually all studies with this assay reportedly involved the use of archival material.
Materials and methods
Random sera were selected from our archival storage bank. Originally all blood samples were refrigerated after venipuncture, centrifuged, aliquoted within 4 h and stored at À80 C. Samples remained frozen until analysis. ACT-complexed PSA was measured utilizing the Bayer Immuno-1 assay according to manufacturer's speci®cations. Sera were initially assayed within 2 weeks of phlebotomy.
The methodology for the cPSA TM utilizing the Bayer method has been previously described. 28 The Bayer Immuno-1 complexed PSA assay is a sandwich immunoassay. A monoclonal PSA antibody conjugated to¯ur-oescein and a polyclonal antibody conjugated to alkaline phosphatase in the presence of an antibody speci®c for free PSA are incubated at 37 C on the Immuno-1 system with patient sample, calibrator or control. Free PSA present in the specimen is bound by the free PSA antibody. The PSA antibody conjugated to alkaline phosphatase reacts with the remaining PSA Ð that which is complexed. The monoclonal immuno-magnetic particle reagent is added to capture the antibody enzyme conjugate complex. Washing of the particles follows. The rate of conversion of substrate to a compound with absorbence at 405 and 450 nm is measured. The measured rate is proportional to the concentration of complexed PSA in the sample.
Eighteen months after the initial determination an additional sample aliquot was assayed. This second determination was performed by a different technician on a different Immuno-1 instrument utilizing different reagent lots used in the ®rst study. Regression analysis and t-test were utilized for analysis.
Results
Sera from 29 patients, ages 49 ± 76 (mean 62), were evaluated. Five men had prostate cancer. Table 1 and Figure 1 show the signi®cant ®ndings. The correlation coef®cient (r 2 1.00) illustrates a high degree of concordance between determinations. Of greater importance is the lack of bias between determinations as evidenced by the slope approaching unity (m 1.01). The t-test con®rmed no signi®cant differences (P 0.9194). These data demonstrate stability of the complexed PSA analyte with long-term storage of 18 months.
Discussion
The ability to enhance PSA speci®city is a laudable goal. Numerous investigators have attempted to achieve this result. The PSA isoforms appear to be the most promising in this regard. The alpha-1 antichymotrypsin complexed PSA, because it is a more speci®c analyte for cancer is most promising. Degradation of the free form of PSA with long-term storage has been well reported.
A number of studies have demonstrated that concentrations and proportions of free and total PSA in serum can dramatically change with time, dependent on the method of storage. 20 ± 23 Jung et al 23 reported that levels of free PSA, total PSA, and the ratio of free-to-total PSA change over time when sera are stored at 4 C over a 2 week time period. The most pronounced decreases were observed for free PSA, an observation that has been con®rmed by others. 22, 24 Arcangeli et al 20 found a signi®cant change from baseline level for free PSA when sera were stored at À20 C compared with À70 C. Over 2 weeks, however, no signi®cant changes were observed for total PSA. Additionally, Woodrum 21 found free PSA values decreased approximately 0.4% per month when stored at À70 C for periods of up to 1 y. The instability of free PSA is presumably due to complexing of free PSA with alpha-2-macroglobulin or other serum substances. 21, 24 In contrast to these reports, other studies have demonstrated stability of complexed PSA in serum and plasma under various storage conditions. Piironen et al 24 reported good stability of PSA-ACT in serum and plasma after 1 week at 4 C and after multiple freeze-thaw cycles at À20 C. Espana et al 25 reported PSA-ACT in Figure 1 18 months stability of cPSA.
Long
C. Furthermore, a recent study determined the stability of complexed PSA in fresh sera from normal men and those of prostate cancer patients with high concentrations of complexed PSA using the Bayer Immuno-1 complexed PSA TM method. 26 They showed that storage at 4 C, À80 C, and over multiple freeze-thaw cycles at À80 C for up to 1 week did not affect recovered complexed PSA values for both normal sera and from prostate cancer patients.
Leionen and Stenman 2 studied stability of free, total and complexed PSA when fresh sera were stored at various temperatures over a period of 3 days and after storage at À20 C for 2 y. They found that values for total and complexed PSA (as determined by subtraction of total minus free PSA) in fresh sera were not signifcantly affected by storage at 4 C. Within 1 day of storage at 4 C, however, free PSA levels decreased, resulting in a decrease in the free/total ratio. For archival sera that were stored at À20 C for 2 y, thawed and tested over the subsequent 11-day period at various temperatures, a small decrease was observed for free PSA, and total PSA values when thawed sera were stored at 4 C. However, major effects were noted when samples were thawed and kept at warmer temperatures for all forms of PSA, suggesting that longterm storage at À20 C reduces the stability of PSA immunoreactivity. The authors suggest that archival sera should be stored at À80 C and tested immediately upon thaw.
This deterioration of archival specimens would make the ratio of free-to-total PSA less speci®c for cancer. This is because the variation of the numerator (free) results in a lower quotient, suggestive of carcinoma. If this occured to a similar degree in men without carcinoma, speci®city would obviously decline. This may have explained in part our initial ®ndings in comparing free-to-total PSA with ACT complexed PSA in men undergoing biopsy. 29 In this study, at the 95% level of sensitivity, complexed PSA provided a speci®city of 26.7% (a signi®cant enhancement over that found with total PSA which afforded speci®city of 21.8%). However, the free-to-total PSA ratio resulted in a speci®city of only 15.6%. The determination of the longterm stability of archival material for evaluation of any assay is required.
In the present investigation, we demonstrated that long-term storage (18 months) at À80 C resulted in essentially no deterioration of the complexed PSA measured with the Bayer lmmuno-1 assay. Moreover, this study was conducted in a`real world' environment where different lots of reagents, instruments and technicians were all used. The ®ndings demonstrate that ACTcomplexed PSA data derived from archival sera is similar to results obtained from fresh specimens.
